Back to News
Market Impact: 0.25

ETF Fundamental Report for IWM

IWMNDAQ
Company FundamentalsAnalyst InsightsHealthcare & BiotechMarket Technicals & FlowsInvestor Sentiment & Positioning
ETF Fundamental Report for IWM

Validea's fundamental report indicates the iShares Russell 2000 ETF (IWM) is a Mid-Cap Value ETF with its largest sector allocation in Services and industry allocation in Biotechnology & Drugs. The ETF exhibits moderate exposure to value (score of 56) and low momentum (score of 41), while showing very low exposure to quality (score of 8) and low volatility (score of 14).

Analysis

According to a fundamental report from Validea, the iShares Russell 2000 ETF (IWM) presents a distinct factor profile for a Mid-Cap Value fund. The ETF demonstrates moderate exposure to the value factor with a score of 56 out of 99, aligning with its classification. However, its exposure to other key factors is notably weak, with a momentum score of 41, a quality score of just 8, and a low volatility score of 14. This composition suggests the underlying portfolio consists of companies that are potentially undervalued but exhibit low financial quality and high price volatility. The fund's largest sector holding is Services, and its largest industry concentration is in Biotechnology & Drugs, a sector known for its high-risk, high-reward characteristics, which further contributes to the ETF's risk profile.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

Ticker Sentiment

IWM0.00
NDAQ0.00

Key Decisions for Investors

  • Investors should be aware of the ETF's very low quality score of 8, indicating that the underlying holdings may possess weaker balance sheets or earnings instability, which could underperform during economic downturns.
  • The low score on the low volatility factor (14) confirms the ETF is prone to significant price swings, making it more suitable for investors with a high risk tolerance.
  • Given the moderate value exposure (56) but low momentum (41), this ETF may appeal to contrarian investors betting on a recovery in out-of-favor small-cap stocks, but it is not aligned with momentum-driven strategies.
  • Prospective buyers should evaluate their portfolio's existing allocation to the Biotechnology & Drugs industry to avoid unintended over-concentration, as this is IWM's single largest industry exposure.